Profile of temsirolimus in the treatment of advanced renal cell carcinoma

Michael StaehlerDepartment of Urology, University of Munich, Klinikum Grosshadern, GermanyCorrespondence[email protected]

Nicolas HasekeDepartment of Urology, University of Munich, Klinikum Grosshadern, Germany

Wael KhoderDepartment of Urology, University of Munich, Klinikum Grosshadern, Germany

Christian G StiefDepartment of Urology, University of Munich, Klinikum Grosshadern, Germany

Pages 191-196 | Published online: 15 Sep 2010

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site [database on the Internet] 2008
Google Scholar
EscudierBEisenTStadlerWMSzczylikCOudardSSiebelsMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
PubMed Web of Science ®Google Scholar
MotzerRJHutsonTETomczakPMichaelsonMDBukowskiRMRixeOSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
PubMed Web of Science ®Google Scholar
HudesGCarducciMTomczakPDutcherJFiglinRKapoorATemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
PubMed Web of Science ®Google Scholar
EscudierBPluzanskaAKoralewskiPRavaudABracardaSSzczylikCBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
PubMed Web of Science ®Google Scholar
AtkinsMBHidalgoMStadlerWMLoganTFDutcherJPHudesGRRandomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaJ Clin Oncol200422590991814990647
PubMed Web of Science ®Google Scholar
MotzerRJBacikJMazumdarMPrognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experienceClin Cancer Res20041018 Pt 26302S6303S15448021
PubMed Web of Science ®Google Scholar
MotzerRJBacikJSchwartzLHReuterVRussoPMarionSPrognostic factors for survival in previously treated patients with metastatic renal cell carcinomaJ Clin Oncol200422345446314752067
PubMed Web of Science ®Google Scholar
LoganTMcDermottDFDutcherJPExploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk featuresJ Clin Oncol200826 (May 20 suppl):abstr 5050.
Web of Science ®Google Scholar
FlaniganRCMickischGSylvesterRTangenCVan PoppelHCrawfordEDCytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysisJ Urol200417131071107614767273
PubMed Web of Science ®Google Scholar
MickischGHGarinAvan PoppelHde PrijckLSylvesterRRadical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialLancet2001358928696696011583750
PubMed Web of Science ®Google Scholar
MotzerRJMazumdarMBacikJBergWAmsterdamAFerraraJSurvival and prognostic stratification of 670 patients with advanced renal cell carcinomaJ Clin Oncol19991782530254010561319
PubMed Web of Science ®Google Scholar
DutcherJPde SouzaPMcDermottDFiglinRABerkenblitAThieleAEffect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologiesMed Oncol200926220220919229667
PubMed Web of Science ®Google Scholar
DutcherJPde SouzaPFiglinREffect of temsirolimus versus interferon-α on survival of patients with advanced renal cell carcinoma of different tumor histologiesClin Oncol200826 (May 20 suppl):abstr 384
Google Scholar
FiglinRAde SouzaPMcDermottDDutcherJPBerkenblitAThieleAAnalysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alphaCancer2009163651366019526589
PubMed Web of Science ®Google Scholar
EscudierBGoupilMGMassardCFizaziKSequential therapy in renal cell carcinomaCancer200911510 Suppl2321232619402067
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Profile of temsirolimus in the treatment of advanced renal cell carcinoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Profile of temsirolimus in the treatment of advanced renal cell carcinoma

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date